prikaz prve stranice dokumenta C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis
  Preuzmi
PDF 1004.25 KB
Znanstveni rad - Izvorni znanstveni rad
C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis
Leukemia & Lymphoma, 61 (2020), 12; 2969-2974. https://doi.org/10.1080/10428194.2020.1789627
Lucijanić, Marko; Galušić, Davor; Krečak, Ivan; Sedinić, Martina; Sorić, Ena; Holik, Hrvoje; Periša, Vlatka; Morić Perić, Martina; Zekanović, Ivan; Štoos-Veić, Tajana; Kušec, Rajko

Citirajte ovaj rad

Lucijanić, M., Galušić, D., Krečak, I., Sedinić, M., Sorić, E., Holik, H. ... Kušec, R. (2020). C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis. Leukemia & Lymphoma, 61. (12), 2969-2974. doi: 10.1080/10428194.2020.1789627

Lucijanić, Marko, et al. "C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis." Leukemia & Lymphoma, vol. 61, br. 12, 2020, str. 2969-2974. https://doi.org/10.1080/10428194.2020.1789627

Lucijanić, Marko, Davor Galušić, Ivan Krečak, Martina Sedinić, Ena Sorić, Hrvoje Holik, Vlatka Periša, et al. "C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis." Leukemia & Lymphoma 61, br. 12 (2020): 2969-2974. https://doi.org/10.1080/10428194.2020.1789627

Lucijanić, M., et al. (2020) 'C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis', Leukemia & Lymphoma, 61(12), str. 2969-2974. doi: 10.1080/10428194.2020.1789627

Lucijanić M, Galušić D, Krečak I, Sedinić M, Sorić E, Holik H, i sur.. C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis. Leukemia & Lymphoma [Internet]. 12.2020. [pristupljeno 02.12.2024.];61(12):2969-2974. doi: 10.1080/10428194.2020.1789627

M. Lucijanić, et al., "C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis", Leukemia & Lymphoma, vol. 61, br. 12, str. 2969-2974, Prosinac 2020. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:774065. [Citirano: 02.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:774065
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis
AutorMarko Lucijanić
AutorDavor Galušić
AutorIvan Krečak
AutorMartina Sedinić
AutorEna Sorić
AutorHrvoje Holik
AutorVlatka Periša
AutorMartina Morić Perić
AutorIvan Zekanović
AutorTajana Štoos-Veić
AutorRajko Kušec
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
We retrospectively investigated C reactive protein to albumin ratio (CAR) in a cohort of 142 patients with myelofibrosis [101 primary (PMF); 41 secondary (SMF)] and compared it to hematological and clinical parameters. Among other associations, higher CAR was significantly associated with higher grade of bone marrow fibrosis, lower frequency of Calreticulin (CALR) mutations, presence of constitutional symptoms, massive splenomegaly, transfusion dependency, blast phase disease, lower hemoglobin, lower platelets, higher ferritin and higher lactate dehydrogenase (LDH) (p < .05 for all analyses). Higher CAR was able to predict inferior survival in PMF independently of DIPSS [hazard ratio (HR)=2.17; p = .015 for high CAR and HR = 2.05; p < .001 for DIPSS] and in SMF independently of Mysec-PM (HR = 6.48; p = .022 for high CAR and HR = 2.63; p = .013 for Mysec-PM) demonstrating its good prognostic potential. CAR seems to be an independent and prognostically relevant parameter, both in PMF and SMF, and might aid in timely recognition of most vulnerable patients.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaLeukemia & Lymphoma
Brojčani podacivol. 61, br. 12, str. 2969-2974
p-ISSN1042-8194
e-ISSN1029-2403
DOIhttps://doi.org/10.1080/10428194.2020.1789627
URN:NBNurn:nbn:hr:105:774065
Datum objave publikacije2020-12
URL dokumentahttps://www.tandfonline.com/doi/full/10.1080/10428194.2020.1789627
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Datum isteka embarga: 2022-01-01
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2021-05-18 12:23:59